Results 261 to 270 of about 234,058 (316)

Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular Therapies. [PDF]

Cancers (Basel)
Tsagkaraki I, Gannon I, Rampotas A, Singh D, Roddy H, Ottaviani D, Roddie C.   +6 more
europepmc   +1 more source

KRAS Inhibitors in Pancreas Cancer: Facts and Hopes about the Immunotherapy We Have All Been Waiting for. [PDF]

Clin Cancer Res
Stanger BZ, Vonderheide RH.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Active Immunotherapy of Cancer

Immunological Investigations, 2015
Clinical progress in the field of cancer immunotherapy has been slow for many years but within the last 5 years, breakthrough successes have brought immunotherapy to the forefront in cancer therapy. Promising results have been observed in a variety of cancers including solid tumors and hematological malignancies with adoptive cell therapy using natural
Thinle, Chodon, Richard C, Koya, Kunle, Odunsi   +2 more
openaire   +2 more sources

Active immunotherapy in colorectal cancer

Seminars in Surgical Oncology, 1989
AbstractSeventy‐four patients with Dukes' B2 through C3 colon or rectal cancer were entered into a prospectively randomized, controlled trial of active specific immunotherapy (ASI) with an autologous tumor cell‐BCG vaccine. Primary tumors were dissociated enzymatically and cryopreserved by techniques that maintain cell viability.
H C, Hoover, M G, Hanna
openaire   +2 more sources

Active immunotherapy of multiple myeloma

European Journal of Cancer, 2006
Since myeloma cells express various potential target antigens, active immunotherapy is being investigated as a novel treatment modality for myeloma. Immunization against the clonal myeloma immunoglobulin (idiotype) elicits protective immunity in mouse models.
Houet, Leonora, Veelken, Hendrik
openaire   +3 more sources

Active specific immunotherapy of melanoma

British Medical Bulletin, 1995
Active specific immunotherapy, or the use of tumor 'vaccines', attempts to stimulate the patient to reject his or her tumor. Nowhere has this approach been utilized more than in melanoma, often with encouraging results. The best results have occurred in the setting of minimal residual disease after resection of the primary tumor and involved lymph ...
openaire   +2 more sources

ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIA

The Lancet, 1969
Abstract Active immunotherapy (with B.C.G. and/or vaccination from a pool of allogeneic leukaemic " lymphoblasts " pretreated with formalin or irradiated in vitro) has been given to patients with acute lymphoblastic leukaemia who had previously been treated by chemotherapy, to induce a remission, and by complementary chemotherapy designed to reduce ...
G, Mathé, J L, Amiel, L, Schwarzenberg, M, Schneider, A, Cattan, J R, Schlumberger, M, Hayat, F, De Vassal   +7 more
openaire   +2 more sources

Active immunotherapy in follicular lymphoma

Seminars in Cancer Biology, 2003
The antigen receptors expressed by follicular lymphomas represent tumor-specific antigens ("idiotypes"). In murine models, vaccination with tumor-derived idiotype in a variety of formulations can induce protective lymphoma-specific immunity. Phase II clinical trials in follicular lymphoma have also demonstrated idiotype-specific immune responses ...
openaire   +3 more sources

ACTIVE SPECIFIC IMMUNOTHERAPY FOR OVARIAN CANCER

The Lancet, 1976
Ten patients with advanced or recurrent ovarian cancer were treated with a combination of chemotherapy and active specific immunotherapy after tumour stasis had been induced. They were inoculated with irradiated allogeneic cryopreserved tumour cells and B.C.G. once monthly in addition to receiving conventional chemotherapy.
C N, Hudson, J E, McHardy, O M, Curling, P E, English, L, Levin, T A, Poulton, M, Crowther, M, Leighton   +7 more
openaire   +2 more sources